TOKYO -- The Nobel Prize shared by Osaka University professor Shimon Sakaguchi for the discovery of regulatory T-cells is boosting joint research partner Chugai Pharmaceutical, as investors hope the Japanese drugmaker's support for basic research will eventually yield new treatments.
Pharmaceuticals
Nobel in medicine shows fruits of Japan's Chugai backing basic research
Drugmaker ties to Osaka University immunology go back to arthritis treatment Actemra
Nobel Prize winner Shimon Sakaguchi, top center, is affiliated with Osaka University's Immunology Frontier Research Center, which collaborates with Chugai Pharmaceutical. (Source photos by Nikkei)
Read Next
Latest on Pharmaceuticals
